2018 Q1 total revenue records a 6% increase year-over-year Focal One Final Additional Information submitted to FDA early May EDAP to attend American Urological Association congress in San Francisco , May 18-21, 2018 LYON, France , May 14, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the
LYON, France , May 2, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2018 , after the close of the financial markets on Monday, May 14, 2018 .
Clinical Results Presented at the Southeastern Section of the American Urological Association Confirms HIFU's Safety, Efficacy and Benefits for Patients' Quality Of Life LYON, FRANCE , AUSTIN, TX -- APRIL 3, 2018 - EDAP TMS (Nasdaq: EDAP) today announced that preliminary results of the first U.S.
2017 Highlights 2017 revenue on par with 2016; lower HIFU capital equipment sales offset by double-digit HIFU treatment revenue growth CMS issued C-Code allocation for reimbursement of HIFU for prostate tissue ablation in July CIGNA to reimburse HIFU as salvage therapy for prostate cancer
Insurer Takes its Cue from Updated NCCN Guidelines, Which Recognizes HIFU as Salvage Treatment for Prostate Cancer Lyon, France , Austin, TX -- March 21, 2018 - EDAP TMS SA (Nasdaq: EDAP) today announced that CIGNA became the first major U.S. private health insurance company to reimburse prostate
LYON, France , March 14, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the year ended December 31, 2017 , after the close of the financial markets on Tuesday, March 27, 2018 .
LYON, France , December 18, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first HIFU treatments performed at Acibadem Hospital , Istanbul, Turkey , using the Company's Focal One Robotic HIFU device. Prof.
EDAP TMS Reports Third Quarter 2017 Results EDAP's HIFU patient treatment revenues grew 29% compared to third quarter 2016. EDAP received FDA clearance for its Ablatherm Fusion ® late in the quarter. EDAP's cash position remains strong at US $21.3 million on September 30, 2017 LYON, France ,
Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 firstname.lastname@example.org Investors: Rich Cockrell CG CAPITAL 877.889.1972 email@example.com Conference Call to Review Results to be Held Thursday, November 16, 2017 LYON, France , November 01, 2017 - EDAP TMS SA
EDAP to Market Echotherapy for ablation of breast fibroadenomas and benign thyroid nodules LYON, France , October 9, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the signature of an Agreement with French HIFU Company Theraclion, to exclusively